Alnylam Pharmaceuticals has dropped its patent infringement lawsuit against Moderna, conceding that Moderna’s COVID-19 vaccine formulation does not infringe on its patents. The case centered around Alnylam’s patent on lipid nanoparticle (LNP) technology used for delivering genetic material into cells. The settlement allows for the entry of judgment in favor of Moderna, effectively ending the legal dispute.